Aducanumab
(Synonyms: BIIB037) 目录号 : GC66406
Aducanumab是一种人源化IgG1单克隆抗体，特异性靶向β-淀粉样蛋白（Aβ）聚集体，包括可溶性寡聚体和纤维状斑块。
Cas No.:1384260-65-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Aducanumab is a humanized IgG1 monoclonal antibody that specifically targets amyloid β (Aβ) aggregates, including soluble oligomers and fibrillar plaques[1]. Aducanumab reduces the amyloid burden in the brains of patients with Alzheimer's disease (AD) by binding to the N-terminal epitope of Aβ and promoting microglia-mediated plaque clearance[2]. Aducanumab is the first antibody approved for the treatment of AD[3]. Aducanumab interacts weakly with Aβ monomers[4].
In vivo, Aducanumab (10mg/kg) was treated intraperitoneally in TgAPPPS1-21 mice for 4 months, which significantly reduced the number of senile plaques in the mouse hippocampus[5]. Aducanumab (3mg/kg) was treated intravenously in 5×FAD mice, which significantly reduced the number of senile plaques in the mouse hippocampus, increased the number of astrocytes, and alleviated cognitive deficits[6].
References:
[1] Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease[J]. Nature, 2016, 537(7618): 50-56.
[2] Kim B H, Kim S, Nam Y, et al. Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives[J]. Translational Neurodegeneration, 2025, 14(1): 6.
[3] Mukhopadhyay S, Banerjee D. A primer on the evolution of aducanumab: the first antibody approved for treatment of Alzheimer’s disease[J]. Journal of Alzheimer's Disease, 2021, 83(4): 1537-1552.
[4] Arndt J W, Qian F, Smith B A, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β[J]. Scientific reports, 2018, 8(1): 6412.
[5] Bastrup J, Hansen K H, Poulsen T B G, et al. Anti-Aβ antibody aducanumab regulates the proteome of senile plaques and closely surrounding tissue in a transgenic mouse model of Alzheimer’s disease[J]. Journal of Alzheimer's Disease, 2021, 79(1): 249-265.
[6] Kong C, Yang E J, Shin J, et al. Enhanced delivery of a low dose of aducanumab via FUS in 5× FAD mice, an AD model[J]. Translational Neurodegeneration, 2022, 11(1): 57.
Aducanumab是一种人源化IgG1单克隆抗体，特异性靶向β-淀粉样蛋白（Aβ）聚集体，包括可溶性寡聚体和纤维状斑块[1]。Aducanumab通过结合Aβ的N端表位，促进小胶质细胞介导的斑块清除，从而减少阿尔茨海默病（AD）患者大脑中的淀粉样蛋白负荷[2]。Aducanumab是第一个被批准用于治疗阿尔茨海默病的抗体[3]。Aducanumab与Aβ单体的相互作用较弱[4]。
在体内，Aducanumab（10mg/kg）通过腹腔注射治疗TgAPPPS1-21小鼠4个月，显著减少了小鼠海马中老年斑数量[5]。Aducanumab（3mg/kg）通过静脉注射治疗5×FAD小鼠，显著减少了小鼠海马中老年斑数量，增加了星形胶质细胞数量，减轻了认知功能缺陷[6]。
| Animal experiment [1]: | |
Animal models | TgAPPPS1-21 mice |
Preparation Method | Mice were randomly divided into three groups; vehicle (PBS; n=4); Aducanumab (n=8); and unspecific IgG (n=10) and injected intraperitoneal (IP) with Aducanumab, unspecific IgG (10mg/kg), or vehicle (PBS) weekly for a four months period. TgAPPPS1-21 mice were anesthetized with a 2% avertin solution and perfused in potassium phosphate buffer saline (PPBS) with 0.3% heparin. The mouse brains were extracted, fresh frozen on dry ice, and stored at -80℃. |
Dosage form | 10mg/kg; weekly dose for four months; i.p. |
Applications | The anti-Aβ antibody Aducanumab reduced the number of senile plaques in hippocampus of tgAPPPS1-21 mice. |
References: | |
| Cas No. | 1384260-65-4 | SDF | Download SDF |
| 别名 | BIIB037 | ||
| 分子式 | 分子量 | ||
| 溶解度 | 储存条件 | Store at -80°C, Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >96.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet